Impact of extending screening mammography to older women Information to support informed choices
Access status:
Open Access
Type
ArticleAuthor/s
Jacklyn, GemmaHoward, Kirsten
Irwig, Les
Houssami, Nehmat
Hersch, Jolyn
Barratt, Alexandra
Abstract
From 2013 through 2017, the Australian national breast cancer screening programme is gradually inviting women aged 70–74 years to attend screening, following a policy decision to extend invitations to older women. We estimate the benefits and harms of the new package of biennial ...
See moreFrom 2013 through 2017, the Australian national breast cancer screening programme is gradually inviting women aged 70–74 years to attend screening, following a policy decision to extend invitations to older women. We estimate the benefits and harms of the new package of biennial screening from age 50–74 compared with the previous programme of screening from age 50–69. Using a Markov model, we applied estimates of the relative risk reduction for breast cancer mortality and the risk of overdiagnosis from the Independent UK Panel on Breast Cancer Screening review to Australian breast cancer incidence and mortality data. We estimated screening specific outcomes (recalls for further imaging, biopsies, false positives, and interval cancer rates) from data published by BreastScreen Australia. When compared with stopping at age 69, screening 1,000 women to age 74 is likely to avert one more breast cancer death, with an additional 78 women receiving a false positive result and another 28 women diagnosed with breast cancer, of whom eight will be overdiagnosed and overtreated. The extra 5 years of screening results in approximately 7 more overdiagnosed cancers to avert one more breast cancer death. Thus extending screening mammography in Australia to older women results in a less favourable harm to benefit ratio than stopping at age 69. Supporting informed decision making for this age group should be a public health priority.
See less
See moreFrom 2013 through 2017, the Australian national breast cancer screening programme is gradually inviting women aged 70–74 years to attend screening, following a policy decision to extend invitations to older women. We estimate the benefits and harms of the new package of biennial screening from age 50–74 compared with the previous programme of screening from age 50–69. Using a Markov model, we applied estimates of the relative risk reduction for breast cancer mortality and the risk of overdiagnosis from the Independent UK Panel on Breast Cancer Screening review to Australian breast cancer incidence and mortality data. We estimated screening specific outcomes (recalls for further imaging, biopsies, false positives, and interval cancer rates) from data published by BreastScreen Australia. When compared with stopping at age 69, screening 1,000 women to age 74 is likely to avert one more breast cancer death, with an additional 78 women receiving a false positive result and another 28 women diagnosed with breast cancer, of whom eight will be overdiagnosed and overtreated. The extra 5 years of screening results in approximately 7 more overdiagnosed cancers to avert one more breast cancer death. Thus extending screening mammography in Australia to older women results in a less favourable harm to benefit ratio than stopping at age 69. Supporting informed decision making for this age group should be a public health priority.
See less
Date
2017Source title
International Journal of CancerVolume
141Issue
12Publisher
WileyLicence
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0Faculty/School
Faculty of Medicine and Health, Sydney School of Public HealthShare